Roche Media News via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Roche Media News' source. Thu, 09 Feb 2012 01:31:36 +0100 Roche disappointed by the actions of Illumina, Inc.'s Board of Directors http://www.medworm.com/index.php?rid=5669456&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-02-08b.htm Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended that shareholders not tender their shares to Roche. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5669456 Wed, 08 Feb 2012 06:00:00 +0100 5669456 FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer http://www.medworm.com/index.php?rid=5669455&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-02-08.htm Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5669455 Wed, 08 Feb 2012 06:00:00 +0100 5669455 Roche in 2011: Strong results and positive outlook http://www.medworm.com/index.php?rid=5651579&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-02-01.htm Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of –12 percentage points due to appreciation of the Swiss franc; overall Group sales at 42.5 billion Swiss francs. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5651579 Wed, 01 Feb 2012 06:00:00 +0100 5651579 Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting http://www.medworm.com/index.php?rid=5651580&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-01-31.htm Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly qualified, independent candidates for election to Illumina’s Board of Directors and propose certain other matters for the consideration of Illumina’s shareholders at Illumina’s 2012 annual meeting, which, if adopted, would result in Roche-nominated directors comprising a majority of the Illumina board. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5651580 Tue, 31 Jan 2012 17:00:00 +0100 5651580 FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma http://www.medworm.com/index.php?rid=5651581&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-01-30.htm Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5651581 Mon, 30 Jan 2012 17:00:00 +0100 5651581 Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash http://www.medworm.com/index.php?rid=5639972&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-01-27b.htm Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, announced today that it has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN). The offer and withdrawal rights are scheduled to expire at 12:00 midnight, New York City time, at the end of the day on February 24, 2012, unless the offer is extended. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5639972 Fri, 27 Jan 2012 16:50:00 +0100 5639972 Roche responds to adoption of shareholder rights plan by Illumina Board of Directors http://www.medworm.com/index.php?rid=5639973&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-01-27.htm Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder rights plan. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5639973 Thu, 26 Jan 2012 23:00:00 +0100 5639973 Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics http://www.medworm.com/index.php?rid=5631218&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-01-25.htm Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5631218 Wed, 25 Jan 2012 02:40:00 +0100 5631218 Roche supports cancer care development program in Ethiopia http://www.medworm.com/index.php?rid=5621717&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2012-01-23.htm Roche today announced a grant to the Albert Einstein College of Medicine of Yeshiva University in New York City, which will be used for the establishment of a program to improve basic cancer care in Ethiopia. The grant funding comes from the Roche African Research Foundation. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5621717 Mon, 23 Jan 2012 09:00:00 +0100 5621717 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer http://www.medworm.com/index.php?rid=5539860&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-12-23.htm Avastin represents first major treatment advance for women with ovarian cancer in 15 years. Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5539860 Fri, 23 Dec 2011 06:00:00 +0100 5539860 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma http://www.medworm.com/index.php?rid=5507601&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-12-16.htm Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5507601 Fri, 16 Dec 2011 12:25:00 +0100 5507601 Changes to the Roche Corporate Executive Committee http://www.medworm.com/index.php?rid=5507602&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-12-15.htm Roche today announced that Sophie Kornowski-Bonnet, currently General Manager of Roche Pharma in France, has been appointed Head of Roche Partnering. Sophie Kornowski-Bonnet will assume her new role on February 1, 2012, and concurrently will join Roche’s enlarged Corporate Executive Committee, reporting to Severin Schwan, CEO of the Roche Group. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5507602 Thu, 15 Dec 2011 06:00:00 +0100 5507602 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer http://www.medworm.com/index.php?rid=5489232&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-12-08.htm Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, Herceptin (trastuzumab) and docetaxel chemotherapy to Herceptin and docetaxel alone in people with previously untreated HER2-positive metastatic breast cancer (mBC). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5489232 Wed, 07 Dec 2011 23:30:00 +0100 5489232 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark http://www.medworm.com/index.php?rid=5460728&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-12-01.htm New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for commercial availability in Europe and other countries that recognize CE mark. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5460728 Thu, 01 Dec 2011 06:00:00 +0100 5460728 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium http://www.medworm.com/index.php?rid=5460729&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-11-30.htm Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 6-10 2011. This includes data from the first randomised Phase III study of pertuzumab in combination with Herceptin and docetaxel chemotherapy (CLEOPATRA). The mechanisms of action of pertuzumab and Herceptin are believed to complement each other as both bind to the HER2 receptor but on different regions. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5460729 Wed, 30 Nov 2011 06:00:00 +0100 5460729 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer http://www.medworm.com/index.php?rid=5424409&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-11-18.htm U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of Avastin’s use for mBC. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5424409 Fri, 18 Nov 2011 16:45:00 +0100 5424409 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer http://www.medworm.com/index.php?rid=5391463&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-11-09.htm Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. The application has been granted Priority Review status and the FDA confirmed the action date is March 8, 2012. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5391463 Wed, 09 Nov 2011 06:00:00 +0100 5391463 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years http://www.medworm.com/index.php?rid=5339160&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-10-20.htm Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease. The study showed that the significant reduction in disease activity as measured by the total number of active brain lesions and relapses previously reported for 24 weeks, was maintained through 96 weeks. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5339160 Thu, 20 Oct 2011 05:00:00 +0100 5339160 Roche reports positive study of Herceptin given by subcutaneous injection http://www.medworm.com/index.php?rid=5326190&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-10-18.htm Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a new, investigational subcutaneous (SC) formulation of Herceptin (trastuzumab) to the standard intravenous (IV) infusion of Herceptin in women with HER2-positive early breast cancer. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5326190 Tue, 18 Oct 2011 05:00:00 +0100 5326190 Roche signs definitive agreement to acquire Anadys Pharmaceuticals http://www.medworm.com/index.php?rid=5326191&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-10-17.htm Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 per share in an all-cash transaction. This corresponds to a total cash consideration of approximately USD 230 million. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5326191 Mon, 17 Oct 2011 05:00:00 +0100 5326191 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches http://www.medworm.com/index.php?rid=5317608&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-10-13.htm Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 billion Swiss francs (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5317608 Thu, 13 Oct 2011 05:00:00 +0100 5317608 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test http://www.medworm.com/index.php?rid=5276989&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-30.htm Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus (HPV) in Swedish women. This is the first major public tender in Europe to screen women using Roche’s HPV test for high risk virus types which potentially can cause cervical cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5276989 Fri, 30 Sep 2011 05:00:00 +0100 5276989 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes http://www.medworm.com/index.php?rid=5263792&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-29.htm Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5263792 Thu, 29 Sep 2011 05:00:00 +0100 5263792 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer http://www.medworm.com/index.php?rid=5253359&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-25.htm Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5253359 Sat, 24 Sep 2011 22:02:00 +0100 5253359 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer http://www.medworm.com/index.php?rid=5253360&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-23.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5253360 Fri, 23 Sep 2011 11:40:00 +0100 5253360 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress http://www.medworm.com/index.php?rid=5229053&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-19.htm Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 September 2011. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5229053 Mon, 19 Sep 2011 05:00:00 +0100 5229053 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year http://www.medworm.com/index.php?rid=5212899&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-08.htm Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5212899 Thu, 08 Sep 2011 09:45:00 +0100 5212899 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer http://www.medworm.com/index.php?rid=5186707&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-09-01.htm Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved Tarceva® (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) in Europe. This approval will enable the use of Tarceva as a first-line monotherapy in people with locally advanced or metastatic NSCLC with EGFR (epidermal growth factor receptor) activating mutations. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5186707 Thu, 01 Sep 2011 05:00:00 +0100 5186707 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer http://www.medworm.com/index.php?rid=5149528&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-08-17.htm Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test. The FDA today also approved the cobas 4800 BRAF V600 Mutation Test, a diagnostic test developed by Roche to identify patients eligible for treatment. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5149528 Wed, 17 Aug 2011 13:55:00 +0100 5149528 Roche's investigational treatment for asthma met its primary endpoint in a phase II study http://www.medworm.com/index.php?rid=5099592&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-08-04.htm Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. In the study, lebrikizumab treatment resulted in a statistically significant increase in FEV1 (measure of lung function) in adults with asthma whose symptoms were inadequately controlled with inhaled corticosteriods (ICS). The overall frequency of adverse events was similar in both the placebo and the treatment group. The results of this study, known as ‘MILLY’, are being published in the New England Journal of Medicine (NEJM) today. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5099592 Thu, 04 Aug 2011 05:00:00 +0100 5099592 Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis http://www.medworm.com/index.php?rid=5090424&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-08-03.htm Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients two years of age and older who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids (medicines used to treat inflammation). RoACTEMRA (known as ACTEMRA outside Europe) can be given alone or in combination with methotrexate in patients with sJIA. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5090424 Wed, 03 Aug 2011 05:00:00 +0100 5090424 "Roche Continents" at the Salzburg Festival celebrates its five-year anniversary http://www.medworm.com/index.php?rid=5072716&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-rochecont2011_200px.jpg Roche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 different nationalities will come together in Salzburg to discuss creativity in the arts and science and uncover common ground in what at first glance appear to be very different disciplines. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5072716 Wed, 27 Jul 2011 07:00:00 +0100 5072716 Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa http://www.medworm.com/index.php?rid=5058984&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-07-25.htm Early testing helps reduce the impact of HIV on infants. Roche announced today that it has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for the support of the Early Infant Diagnosis (EID) Programme. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5058984 Mon, 25 Jul 2011 07:00:00 +0100 5058984 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer http://www.medworm.com/index.php?rid=5054572&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-07-22.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a genetically distinct type of non-small cell lung cancer (NSCLC). The proposed use of Tarceva is for first-line monotherapy in people diagnosed with advanced EGFR (epidermal growth factor receptor) activating mutation positive NSCLC. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5054572 Fri, 22 Jul 2011 13:20:00 +0100 5054572 Roche on track - full year earnings outlook increased http://www.medworm.com/index.php?rid=5043459&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-07-21.htm Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5043459 Thu, 21 Jul 2011 05:00:00 +0100 5043459 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing http://www.medworm.com/index.php?rid=5043460&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-07-19.htm Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5043460 Tue, 19 Jul 2011 05:00:00 +0100 5043460 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse http://www.medworm.com/index.php?rid=5032425&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-07-15.htm Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=5032425 Fri, 15 Jul 2011 05:00:00 +0100 5032425 Roche’s Avastin receives broader EU label for women with metastatic breast cancer http://www.medworm.com/index.php?rid=4988330&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-30b.htm Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast cancer label to include combination with Xeloda (capecitabine). The European Commission had recently confirmed the approval of Avastin in combination with paclitaxel chemotherapy for women with metastatic breast cancer in the first-line setting. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4988330 Thu, 30 Jun 2011 05:01:00 +0100 4988330 Roche provides update from FDA hearing on Avastin for metastatic breast cancer http://www.medworm.com/index.php?rid=4988329&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-30.htm FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin (bevacizumab) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative metastatic breast cancer. The committee’s recommendation is not the final decision and Avastin plus paclitaxel is still FDA approved for women with HER2-negative metastatic breast cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4988329 Thu, 30 Jun 2011 05:01:00 +0100 4988329 Roche and Evotec to jointly develop biomarkers in oncology http://www.medworm.com/index.php?rid=4963706&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-24.htm Roche and Evotec AG today announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4963706 Fri, 24 Jun 2011 05:00:00 +0100 4963706 Roche sets up R&D Institute in France to foster collaborative translational research http://www.medworm.com/index.php?rid=4963707&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-23.htm Roche announced today the launch of a new R&D Institute in France under the lead of the company's Pharma Research and Early Development (pRED) unit. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4963707 Thu, 23 Jun 2011 10:00:00 +0100 4963707 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer http://www.medworm.com/index.php?rid=4948108&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-20.htm Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4948108 Mon, 20 Jun 2011 05:00:00 +0100 4948108 Roche Children's Walk 2011: Employees worldwide walk on the same day to raise awareness for vulnerable children in Malawi and around the world http://www.medworm.com/index.php?rid=4940804&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-16.htm Every year since 2003 Roche employees raise awareness for children in need by walking to collect donations for day-care centres in Malawi and children’s charities in their own countries. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4940804 Thu, 16 Jun 2011 08:00:00 +0100 4940804 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations http://www.medworm.com/index.php?rid=4897635&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-05.htm Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival (OS) in people with previously untreated BRAF V600 mutation-positive metastatic melanoma, compared to chemotherapy. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4897635 Sun, 05 Jun 2011 15:00:00 +0100 4897635 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer http://www.medworm.com/index.php?rid=4897636&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-04.htm Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4897636 Sat, 04 Jun 2011 15:30:00 +0100 4897636 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse http://www.medworm.com/index.php?rid=4897637&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-03.htm Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC showed that first-line Tarceva nearly doubled the time people with NSCLC with EGFR activating mutations lived without their disease getting worse compared with chemotherapy (median progression-free survival or PFS: 9.7 months compared with 5.2 months). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4897637 Fri, 03 Jun 2011 05:00:00 +0100 4897637 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer http://www.medworm.com/index.php?rid=4887975&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-06-02.htm Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers Squibb’s ipilimumab in patients with BRAF-mutated metastatic melanoma. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4887975 Thu, 02 Jun 2011 11:00:00 +0100 4887975 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis http://www.medworm.com/index.php?rid=4867177&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-05-26.htm New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4867177 Thu, 26 May 2011 05:00:00 +0100 4867177 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse http://www.medworm.com/index.php?rid=4835270&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-05-19.htm Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4835270 Thu, 19 May 2011 05:00:00 +0100 4835270 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO http://www.medworm.com/index.php?rid=4835271&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-05-18.htm Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4835271 Wed, 18 May 2011 05:00:00 +0100 4835271 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C http://www.medworm.com/index.php?rid=4835272&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-05-17.htm Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in the United States. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4835272 Tue, 17 May 2011 15:30:00 +0100 4835272 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer http://www.medworm.com/index.php?rid=4808326&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-05-11.htm Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) for approval for people with BRAF V600 mutation-positive metastatic melanoma. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4808326 Wed, 11 May 2011 05:00:00 +0100 4808326 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer http://www.medworm.com/index.php?rid=4728287&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fhpv_kit_200px.jpg Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4728287 Wed, 20 Apr 2011 05:00:00 +0100 4728287 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) http://www.medworm.com/index.php?rid=4728288&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-04-18.htm Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate in patients with SJIA. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4728288 Mon, 18 Apr 2011 05:00:00 +0100 4728288 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe http://www.medworm.com/index.php?rid=4716732&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-04-15.htm Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4716732 Fri, 15 Apr 2011 11:30:00 +0100 4716732 Roche Group's first-quarter 2011 sales on track for full-year targets - positive results in seven key clinical trials http://www.medworm.com/index.php?rid=4711575&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-04-14.htm Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss francs, +4% in US dollars). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4711575 Thu, 14 Apr 2011 05:00:00 +0100 4711575 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer http://www.medworm.com/index.php?rid=4689041&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Ftdm1-her2.jpg Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known as TDM4450g, compared trastuzumab emtansine (T-DM1) single agent to the combination of Herceptin (trastuzumab) and chemotherapy (docetaxel) in previously untreated patients. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4689041 Thu, 07 Apr 2011 05:00:00 +0100 4689041 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma http://www.medworm.com/index.php?rid=4618483&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-03-21.htm Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer. The study met its primary endpoint (overall response rate), of showing vismodegib shrank tumours in a pre-defined percentage of people in the study. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4618483 Mon, 21 Mar 2011 06:00:00 +0100 4618483 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics http://www.medworm.com/index.php?rid=4585417&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-03-15.htm Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in providing customised automation and workflow solutions for in-vitro diagnostic (IVD) testing in large commercial and hospital laboratories. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4585417 Tue, 15 Mar 2011 07:45:00 +0100 4585417 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer http://www.medworm.com/index.php?rid=4537776&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-03-02.htm Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4537776 Wed, 02 Mar 2011 06:00:00 +0100 4537776 Roche Annual General Meeting: dividend raised by 10% http://www.medworm.com/index.php?rid=4534173&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-03-01.htm Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total of 160,000,000 bearer shares, approved the 2010 Annual Report and financial statements. They also authorised a dividend increase of 10% to 6.60 Swiss francs per share and non-voting equity. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4534173 Tue, 01 Mar 2011 12:45:00 +0100 4534173 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer http://www.medworm.com/index.php?rid=4447560&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-02-08.htm Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4447560 Tue, 08 Feb 2011 06:00:00 +0100 4447560 Solid overall results http://www.medworm.com/index.php?rid=4426198&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-02-02.htm Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4426198 Wed, 02 Feb 2011 06:00:00 +0100 4426198 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma http://www.medworm.com/index.php?rid=4416254&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-01-31.htm Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan/MabThera plus chemotherapy (induction treatment). This milestone follows the clearance of MabThera for this indication by the European Commission in October 2010. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4416254 Mon, 31 Jan 2011 06:00:00 +0100 4416254 Early successful readout of Tarceva study in a distinct form of lung cancer http://www.medworm.com/index.php?rid=4408236&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-01-28.htm Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim analysis it was shown that compared to platinum-based chemotherapy Tarceva® (erlotinib) significantly extended the time people with newly diagnosed advanced non small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) activating mutations lived without their disease getting worse (progression-free survival or PFS). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4408236 Fri, 28 Jan 2011 06:00:00 +0100 4408236 Roche personalized investigational medicine shows survival benefit in advanced skin cancer http://www.medworm.com/index.php?rid=4365770&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-01-19.htm Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4365770 Wed, 19 Jan 2011 06:00:00 +0100 4365770 Changes to the Roche Corporate Executive Committee http://www.medworm.com/index.php?rid=4357814&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2011-01-17.htm Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans to focus on a number of board memberships. The Board of Directors of Roche Holding Ltd thanks Erich Hunziker for his many years of exceptional service and outstanding contributions to the Group’s success. The Board of Directors has appointed Alan Hippe to succeed Erich Hunziker as Chief Financial Officer. Alan Hippe will join Roche as a member of the Corporate Executive Committee as of April 2011. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4357814 Mon, 17 Jan 2011 06:00:00 +0100 4357814 FDA grants supplemental approval for ACTEMRA http://www.medworm.com/index.php?rid=4311265&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-0050813-actemra-rheumatoid-200px.jpg Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4311265 Wed, 05 Jan 2011 16:30:00 +0100 4311265 Roche provides update on Avastin for metastatic breast cancer following reviews in Europe and the United States http://www.medworm.com/index.php?rid=4269444&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-16.htm Roche confirmed that following the reviews of Avastin (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4269444 Thu, 16 Dec 2010 16:30:00 +0100 4269444 Roche announces change in Board of Directors http://www.medworm.com/index.php?rid=4255798&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-13.htm Roche announced today that Walter Frey and Wolfgang Ruttenstorfer will not stand for re-election to the Board of Directors. Paul Bulcke (CEO of Nestlé), Christoph Franz (Chairman of the Executive Board & CEO Deutsche Lufthansa AG as of January 2011) and Peter Voser (CEO of Royal Dutch Shell plc) will be proposed for appointment to the Board of Directors at the 2011 Annual General Meeting. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4255798 Mon, 13 Dec 2010 06:00:00 +0100 4255798 Pertuzumab and Herceptin plus chemotherapy significantly improved the rate of complete tumour disappearance in study of women with newly diagnosed, early-stage HER2-positive breast cancer http://www.medworm.com/index.php?rid=4247541&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-10.htm Phase II study evaluating a novel targeted combination regimen showed promising results in the neoadjuvant (pre-surgery) setting. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4247541 Fri, 10 Dec 2010 14:00:00 +0100 4247541 Roche provides update on leading late-stage pharmaceutical pipeline http://www.medworm.com/index.php?rid=4243613&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-09.htm Roche today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas. The London investor event will focus on major progress that has been achieved in recent months with Roche’s late-stage pipeline assets in the areas of oncology and CNS, as well as on further development plans of these potential breakthrough medicines. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4243613 Thu, 09 Dec 2010 06:00:00 +0100 4243613 New Phase II data from investigational compound GA101 presented today at the American Society of Hematology http://www.medworm.com/index.php?rid=4231757&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-06.htm Roche announced today new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory Non-Hodgkin’s Lymphoma (NHL), a common type of blood cancer. GA101 is the first type II, glycoengineered anti-CD20 monoclonal antibody that has been specifically designed to enhance the destruction of cancerous B-cells either by activating other immune cells to attack the cancer cells or by inducing direct cell death. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4231757 Mon, 06 Dec 2010 06:00:00 +0100 4231757 Phase II study with first-in-class investigational drug demonstrates improvement in negative symptoms in patients with schizophrenia http://www.medworm.com/index.php?rid=4231756&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-06b.htm Roche today presented eight-week results from a phase II study of RG1678, its investigational first-in-class glycine reuptake inhibitor (GRI) for the treatment of schizophrenia. The data showed a clinically meaningful reduction in the negative symptoms of schizophrenia, accompanied by beneficial changes in patients’ personal and social functioning. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4231756 Mon, 06 Dec 2010 06:00:00 +0100 4231756 Phase III study showed Rituxan/MabThera for initial use followed by continued use delayed need for additional therapy in people with asymptomatic follicular lymphoma, a common type of blood cancer http://www.medworm.com/index.php?rid=4229586&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-12-05.htm Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%. Roche announced today positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4229586 Sun, 05 Dec 2010 13:00:00 +0100 4229586 Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test http://www.medworm.com/index.php?rid=4194117&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-11-23.htm Molecular assay aims to enhance personalized treatment with Tarceva by detecting EGFR activating mutations. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4194117 Tue, 23 Nov 2010 06:00:00 +0100 4194117 Roche launches new cobas blood gas analyzer http://www.medworm.com/index.php?rid=4194118&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fcobas_b123_200px.jpg Roche announced today to introduce its new blood gas analyzer, the cobas b 123 POC system, in Europe and several markets in Latin America, Middle East, Africa and the Asia-Pacific region. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4194118 Mon, 22 Nov 2010 06:00:00 +0100 4194118 Roche announces implementation plans for its Operational Excellence Program http://www.medworm.com/index.php?rid=4173653&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-11-17.htm Measures aim to strengthen innovation and ensure sustained success in a fast changing market environment. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4173653 Wed, 17 Nov 2010 06:00:00 +0100 4173653 Roche reports promising Phase II results with new targeted approach in advanced melanoma http://www.medworm.com/index.php?rid=4137042&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-11-04.htm Roche today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4137042 Thu, 04 Nov 2010 22:05:00 +0100 4137042 MabThera approved in Europe for first line maintenance treatment of follicular lymphoma, a common type of blood cancer http://www.medworm.com/index.php?rid=4113402&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-29.htm Roche announced today that the European Commission has approved the use of MabThera (rituximab) as a maintenance treatment for people suffering from follicular lymphoma who have responded to initial induction therapy. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4113402 Fri, 29 Oct 2010 05:00:00 +0100 4113402 FDA approves Herceptin for HER2-positive metastatic stomach cancer http://www.medworm.com/index.php?rid=4092556&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-21.htm First targeted medicine shown to improve overall survival in HER2-positive stomach and gastroesophageal junction cancers. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4092556 Thu, 21 Oct 2010 05:00:00 +0100 4092556 Phase II study with ocrelizumab shows significant reduction in disease activity for multiple sclerosis patients http://www.medworm.com/index.php?rid=4070494&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-15b.htm Roche and Biogen Idec (NASDAQ: BIIB) today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate. Patients with RRMS suffer from relapses and disabling symptoms caused by nerve damage which can significantly affect their quality of life. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4070494 Fri, 15 Oct 2010 13:30:00 +0100 4070494 Roche Group posts solid sales growth in first nine months http://www.medworm.com/index.php?rid=4070495&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-14.htm Group sales increase 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs in first nine months of 2010. Excluding Tamiflu, Group sales rise 6% (3% in Swiss francs, 7% in US dollars). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4070495 Thu, 14 Oct 2010 05:00:00 +0100 4070495 Roche reports positive data for Avastin in ovarian cancer and T-DM1 in breast cancer http://www.medworm.com/index.php?rid=4054560&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-11b.htm Encouraging new data released at ESMO congress. Ovarian cancer: Data from second positive phase III study of Avastin (ICON7) add further evidence to the potential of Avastin in ovarian cancer where there have been few major treatment advances in the past decade. Metastatic breast cancer: T-DM1 achieves efficacy comparable to standard of care while significantly reducing the burden of typical side effects associated with conventional chemotherapy. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4054560 Mon, 11 Oct 2010 13:00:00 +0100 4054560 MetMAb, a new compound under investigation, extends the time people with lung cancer live without their disease getting worse http://www.medworm.com/index.php?rid=4052297&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-09.htm Important new data in lung cancer presented at ESMO, including further evidence of strong efficacy of Tarceva in lung cancer with genetic mutations. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4052297 Sat, 09 Oct 2010 09:00:00 +0100 4052297 Roche buys full rights to danoprevir from InterMune http://www.medworm.com/index.php?rid=4038748&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-10-07.htm Roche today announced that it has bought full worldwide development and commercialization rights to danoprevir (RG7227/ITMN-191) from InterMune, Inc. (NASDAQ: ITMN) for USD 175 million. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=4038748 Thu, 07 Oct 2010 05:00:00 +0100 4038748 Roche recognised as global healthcare leader in Dow Jones Sustainability Index http://www.medworm.com/index.php?rid=3949046&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-09-09.htm Roche has been named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for the second year running. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3949046 Thu, 09 Sep 2010 10:15:00 +0100 3949046 Roche announces Operational Excellence initiative http://www.medworm.com/index.php?rid=3926856&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-09-03.htm Roche today announced the launch of a Group-wide Operational Excellence initiative. In view of mounting pressures to curb healthcare costs – especially in the United States and Europe – together with recent developments in late-stage projects in the Roche pipeline, this initiative aims to adapt cost structures and accelerate productivity improvements Group-wide. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3926856 Fri, 03 Sep 2010 05:00:00 +0100 3926856 6th Roche Commission goes to Sofia Gubaidulina http://www.medworm.com/index.php?rid=3909879&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fsofia_200px.jpg This Saturday, Roche will be presenting its 6th Commission to a contemporary composer. Together with the Lucerne Festival, the Cleveland Orchestra and Carnegie Hall, Roche has decided to commission a sixth piece of music in the Roche Commission series to Sofia Gubaidulina. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3909879 Fri, 27 Aug 2010 09:00:00 +0100 3909879 Roche provides update on FDA application for T-DM1 http://www.medworm.com/index.php?rid=3905781&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-08-27.htm Roche expects a global regulatory submission mid 2012. Roche today announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company’s trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study. Roche will continue to work with the FDA and expects a global regulatory submission of T-DM1 mid 2012. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3905781 Fri, 27 Aug 2010 05:00:00 +0100 3905781 Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions http://www.medworm.com/index.php?rid=3891126&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-08-23.htm Acquisition further strengthens Roche’s global leadership in tissue-based cancer diagnostics and research. Roche announced today that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California. The purchase price is approximately 100 million US dollars on a debt-free basis. The transaction is subject to customary closing conditions and is expected to close in the coming weeks. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3891126 Mon, 23 Aug 2010 05:00:00 +0100 3891126 Fourth Roche Continents study week for 100 students http://www.medworm.com/index.php?rid=3797086&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-rochecontinents-200px.gif For the fourth time, Roche and the Salzburg Festival have invited 100 students to take part in Roche Continents. Science, music and art students from 43 different countries will be spending a week together in Salzburg discussing creativity in their respective fields of study and uncovering the common ground in what at first glance appear to be very different disciplines. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3797086 Wed, 28 Jul 2010 07:00:00 +0100 3797086 Roche posts good half year results http://www.medworm.com/index.php?rid=3774739&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-07-22.htm Operating profit increases significantly faster than sales – double-digit growth for Core Earnings per share – outlook confirmed (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3774739 Thu, 22 Jul 2010 05:00:00 +0100 3774739 Roche launches new immunoassay module for large volume laboratories http://www.medworm.com/index.php?rid=3770428&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fcobas_e602_200px.jpg Roche announced today the launch of the cobas e 602 module for immunoassay testing as the latest addition to its cobas 8000 platform. This product is now available in Europe as well as in all countries recognizing the CE Mark in the Latin America and Asia-Pacific regions. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3770428 Tue, 20 Jul 2010 15:30:00 +0100 3770428 A New Study Shows that Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test http://www.medworm.com/index.php?rid=3735616&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-07-08.htm 1 in 10 women in the ATHENA trial, age 30-years and older, who tested positive for HPV genotypes 16 and/or 18 by the cobas 4800 HPV Test had cervical pre-cancer, although their Pap test was normal. Involving more than 47,000 women, the ATHENA trial is the largest registration study ever conducted for cervical cancer screening. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3735616 Thu, 08 Jul 2010 15:30:00 +0100 3735616 Roche submits application to FDA for trastuzumab-DM1 in previously treated advanced HER2-positive breast cancer http://www.medworm.com/index.php?rid=3728369&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-07-07.htm Roche today announced that the company submitted a Biologics Licence Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3728369 Wed, 07 Jul 2010 05:00:00 +0100 3728369 Second phase III study showed Avastin-containing regimen helped women with ovarian cancer live longer without their disease getting worse http://www.medworm.com/index.php?rid=3716745&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-07-02.htm Roche announced today that a second large, phase III, international study showed that the combination of Avastin (bevacizumab) and chemotherapy followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone. Adverse events were consistent with those observed in pivotal trials of Avastin. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3716745 Fri, 02 Jul 2010 05:00:00 +0100 3716745 RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis http://www.medworm.com/index.php?rid=3669321&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-0050813-actemra-rheumatoid-200px.jpg Roche today announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3669321 Fri, 18 Jun 2010 05:00:00 +0100 3669321 Roche's MabThera is the first and only licensed biologic to offer a targeted B cell approach to rheumatoid arthritis (RA) treatment http://www.medworm.com/index.php?rid=3669322&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-actemra43-200px.jpg Experts at this year's European League Against Rheumatism (EULAR) annual congress highlighted to rheumatologists that targeted treatment in RA, through the testing of specific blood markers at the time of diagnosis, could have a significant impact on treatment decisions, resulting in an improvement in patient quality of life. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3669322 Thu, 17 Jun 2010 06:30:00 +0100 3669322 All around the world: Roche Children's Walk to take place on International Day of the African Child http://www.medworm.com/index.php?rid=3664497&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmalawi_school_200px.jpg For many years, Roche employees at company sites around the world have been showing solidarity with children in need by supporting day-care centres in Malawi and children's charities in their own countries. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3664497 Wed, 16 Jun 2010 08:00:00 +0100 3664497 Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening http://www.medworm.com/index.php?rid=3633046&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-06-06.htm Roche today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3633046 Sun, 06 Jun 2010 13:00:00 +0100 3633046 Roche presents early data on the next generation of therapeutic antibodies and other targeted therapies at ASCO http://www.medworm.com/index.php?rid=3627796&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-06-04.htm Roche today provided an overview of the new medicines in early-stage studies that will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 4-8 in Chicago. The combined Roche and Genentech oncology pipeline includes 22 new investigational medicines in clinical development of which five are expected to be submitted for regulatory approval by 2013. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3627796 Fri, 04 Jun 2010 13:00:00 +0100 3627796 Roche's Newly Launched Next-Generation DNA Sequencer Opens Innovation in Genomic Research to Broad Scientific Community http://www.medworm.com/index.php?rid=3601855&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-05-27.htm Roche announced today the global launch of the GS Junior System, the company’s new benchtop next-generation DNA sequencing platform for life science research. The GS Junior System, developed by 454 Life Sciences, a Roche company, provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3601855 Thu, 27 May 2010 05:00:00 +0100 3601855 Roche to Present New Data on Different Approaches To Treating Cancer at ASCO http://www.medworm.com/index.php?rid=3583771&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-05-21b.htm Roche today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3583771 Thu, 20 May 2010 22:00:00 +0100 3583771 Phase III study showed first-line maintenance use of MabThera doubles likelihood of people with follicular lymphoma living without their disease worsening http://www.medworm.com/index.php?rid=3583772&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-05-21.htm Roche announced today data from the Phase III PRIMA study. The data showed that continuing MabThera (rituximab) for two years in patients who responded to initial treatment with MabThera plus chemotherapy, doubled the likelihood of them living without their disease worsening, known as progression-free survival (PFS), compared to those who did not receive maintenance. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3583772 Thu, 20 May 2010 17:45:00 +0100 3583772 Roche and Biogen Idec announce their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis http://www.medworm.com/index.php?rid=3575551&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-05-19.htm Roche and Biogen Idec today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3575551 Wed, 19 May 2010 05:00:00 +0100 3575551 Roche announces joint initiative to train healthcare workers in Africa's fight against cancer http://www.medworm.com/index.php?rid=3509958&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-04-28.htm Roche announced today the launch of the EDUCARE (EDUcation for Cancer in African REgions) project, which, in concert with IAEA (International Atomic Energy Agency), will provide support to help combat the growing cancer epidemic in sub-Saharan Africa. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3509958 Wed, 28 Apr 2010 11:30:00 +0100 3509958 Excellent growth in first quarter of 2010 http://www.medworm.com/index.php?rid=3470109&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-04-15.htm Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss francs, +15% in US dollars); Both divisions continue to outgrow their respective markets in 2010; Roche confirms full-year outlook (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3470109 Thu, 15 Apr 2010 05:00:00 +0100 3470109 Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market http://www.medworm.com/index.php?rid=3462108&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-04-13.htm Roche and Elron Electronics Ltd. announced today that they have signed an agreement under which Roche will acquire 100% of Medingo Ltd., a majority-owned subsidiary of the Elron group. Medingo Ltd. is engaged in the development of a semi-disposable insulin patch pump. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3462108 Tue, 13 Apr 2010 05:00:00 +0100 3462108 Xeloda in combination with oxaliplatin approved in Europe for the adjuvant treatment of patients with early colon cancer http://www.medworm.com/index.php?rid=3418762&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-30.htm Roche announced today that Xeloda (capecitabine) in combination with oxaliplatin (a combination known as XELOX) has been approved by the European Medicines Agency (EMEA) for the adjuvant (post-surgery) treatment of patients with early colon cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3418762 Tue, 30 Mar 2010 05:00:00 +0100 3418762 Management Change Group Communications http://www.medworm.com/index.php?rid=3401588&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-25.htm Effective June 1, 2010 Per-Olof Attinger, currently Head Group Communications and Member of the Enlarged Corporate Executive Committee, will take over the position as Head CEO Office and Secretary to the Corporate Executive Committee reporting to Severin Schwan. Effective August 1, 2010 Stephan Feldhaus will be appointed Head Group Communications and Member of the Enlarged Corporate Executive Committee, reporting to Severin Schwan. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3401588 Thu, 25 Mar 2010 06:00:00 +0100 3401588 Roche uniquely positioned to deliver long-term growth http://www.medworm.com/index.php?rid=3376456&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-18.htm Leading late-stage pipeline and innovation strategy presented at investor conference. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3376456 Thu, 18 Mar 2010 06:00:00 +0100 3376456 Roche provides update on phase III study of Avastin in men with late stage prostate cancer http://www.medworm.com/index.php?rid=3356882&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-12.htm Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3356882 Fri, 12 Mar 2010 06:00:00 +0100 3356882 Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold http://www.medworm.com/index.php?rid=3341013&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-08.htm Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3341013 Mon, 08 Mar 2010 06:00:00 +0100 3341013 Roche Annual General Meeting: dividend raised by 20% http://www.medworm.com/index.php?rid=3320449&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-02.htm Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 698 shareholders in attendance, representing 143,055,648, or 89.4% of a total of 160,000,000 bearer shares, approved the 2009 Annual Report and financial statements. They also authorised a +20% increase in the dividend to 6.00 Swiss francs per share and non-voting equity. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3320449 Tue, 02 Mar 2010 12:30:00 +0100 3320449 Avastin phase III study shows positive results in women with advanced ovarian cancer http://www.medworm.com/index.php?rid=3304809&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-25.htm Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3304809 Thu, 25 Feb 2010 06:00:00 +0100 3304809 Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint http://www.medworm.com/index.php?rid=3296759&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-23.htm Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). The study, known as AVAGAST, did not meet its primary endpoint of extending overall survival in patients treated with Avastin in combination with chemotherapy compared to the same chemotherapy plus placebo. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296759 Tue, 23 Feb 2010 06:00:00 +0100 3296759 US FDA approves Rituxan/MabThera for the most common type of adult leukemia http://www.medworm.com/index.php?rid=3296760&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-19.htm Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296760 Fri, 19 Feb 2010 06:00:00 +0100 3296760 Roche study drug may offer valuable new treatment option for patients with type 2 diabetes http://www.medworm.com/index.php?rid=3296761&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-11.htm Roche announced today that results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose (blood sugar) in these studies. Roche’s taspoglutide, the first weekly human GLP-1 analogue in late stage development may improve treatment options for patients with type 2 diabetes. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296761 Thu, 11 Feb 2010 06:00:00 +0100 3296761 Strong operating performance for Roche in 2009 http://www.medworm.com/index.php?rid=3296762&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-03.htm Record sales, double-digit growth in operating profit and Core Earnings per share – Dividend increase by 20% to 6.00 Swiss francs proposed - Group sales increase by 10% to 49.1 billion Swiss francs (8% in Swiss francs, 7% in US dollars). Both divisions gain market share. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296762 Wed, 03 Feb 2010 06:00:00 +0100 3296762 Roche establishes new medical research hub in Singapore http://www.medworm.com/index.php?rid=3296764&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28b.htm Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296764 Thu, 28 Jan 2010 06:00:00 +0100 3296764 Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer http://www.medworm.com/index.php?rid=3296763&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28.htm Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which showed that treatment with Herceptin significantly prolongs the lives of patients with this aggressive cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296763 Thu, 28 Jan 2010 06:00:00 +0100 3296763 Roche establishes new medical research hub in Singapore http://www.medworm.com/index.php?rid=3214788&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28b.htm Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3214788 Thu, 28 Jan 2010 06:00:00 +0100 3214788 Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer http://www.medworm.com/index.php?rid=3214787&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28.htm Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which showed that treatment with Herceptin significantly prolongs the lives of patients with this aggressive cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3214787 Thu, 28 Jan 2010 06:00:00 +0100 3214787 Roche invests about 190 Mio Swiss Francs in infusion-free administration device with new Herceptin formulation http://www.medworm.com/index.php?rid=3296765&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-20.htm Roche is investing about 190 Mio Swiss Francs at its production sites in Kaiseraugst, Switzerland, and Mannheim, Germany, to manufacture a patient-friendly device which might for the first time allow patients to self-administer biological cancer medicines. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296765 Wed, 20 Jan 2010 06:00:00 +0100 3296765 FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis http://www.medworm.com/index.php?rid=3296766&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-actemra39-200px.jpg First-in-class biologic therapy, IL-6 receptor-inhibiting monoclonal antibody approved based on largest clinical development program in rheumatoid arthritis to date. Roche today announced that the United States (US) Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296766 Mon, 11 Jan 2010 06:00:00 +0100 3296766 Roche presents Building 1, its new main office building in Basel http://www.medworm.com/index.php?rid=3296767&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fbau1_200px.jpg Today Roche is unveiling the plans for Building 1, the new office building that the company intends to build at its Basel site. The project, which will accommodate some 1900 attractively designed workplaces, is the alternative to the “Twist 2 Spirals” scheme that the company decided not to continue a year ago. It meets all Roche’s requirements in terms of functionality and engineering. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296767 Thu, 17 Dec 2009 13:00:00 +0100 3296767 Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin http://www.medworm.com/index.php?rid=3296768&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-12.htm Today, Roche announced new long-term follow up-data from two large pivotal studies evaluating adjuvant Herceptin in HER2-positive early- stage breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3296768 Sat, 12 Dec 2009 15:45:00 +0100 3296768 Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer http://www.medworm.com/index.php?rid=3081423&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-11.htm Roche today announced results from a phase III study (RIBBON 2) of Avastin (bevacizumab) in women with advanced HER2-negative breast cancer who had previously received chemotherapy as first-line treatment. The study showed that women who received Avastin in combination with commonly used chemotherapies as second-line treatment had a 28% improvement in the chance of being alive without the disease getting worse (progression-free survival or PFS) compared to chemotherapy alone. Adverse events were consistent with those previously reported for Avastin and no new Avastin safety findings were observed in the study. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3081423 Fri, 11 Dec 2009 18:30:00 +0100 3081423 First Phase III study evaluating Roche's ocrelizumab in patients with rheumatoid arthritis meets primary endpoint http://www.medworm.com/index.php?rid=3077725&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-11b.htm Roche announced today that STAGE, a Phase III trial evaluating ocrelizumab as a treatment for seropositive rheumatoid arthritis (RA) patients with a previous inadequate response to methotrexate (MTX), met its primary efficacy endpoint. The study shows that patients treated with ocrelizumab in combination with MTX achieved the primary efficacy endpoint, which was a co-primary endpoint measured by an improvement in the signs and symptoms of their disease (ACR20 response) both at week 24 and week 48, compared to those treated with MTX alone. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3077725 Fri, 11 Dec 2009 06:00:00 +0100 3077725 Roche Introduces New Automated Clinical Laboratory System for CE-Marked Testing of Human Papillomavirus, Chlamydia and N. gonorrhoeae http://www.medworm.com/index.php?rid=3073768&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2F0150540_cobas4800_200px.jpg Roche announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas 4800 System combines CE-marked in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3073768 Wed, 09 Dec 2009 17:00:00 +0100 3073768 Important progress in treatment of early and late stage breast cancer with Herceptin, Avastin and T-DM1 http://www.medworm.com/index.php?rid=3069401&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-09.htm Roche to present new results that could offer a better future to women with early and very advanced breast cancer, at the CTRC-AACR San Antonio Breast Cancer Symposium (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3069401 Wed, 09 Dec 2009 06:00:00 +0100 3069401 MabThera/Rituxan is the first treatment to show improved overall survival in previously untreated patients with chronic lymphocytic leukemia http://www.medworm.com/index.php?rid=3065470&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today at the 51st Meeting of the American Society of Hematology (ASH) in New Orleans, LA (USA) that the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with MabThera/Rituxan (rituximab) compared to chemotherapy alone. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3065470 Tue, 08 Dec 2009 06:00:00 +0100 3065470 MabThera/Rituxan: promising new data in leukemia and lymphatic cancers to be presented at the American Society of Hematology (ASH), the world's leading meeting in blood cancers http://www.medworm.com/index.php?rid=3054835&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-04.htm Roche announced today that updated results of the pivotal phase III study, CLL8, will be one of many key presentations at the forthcoming 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3054835 Fri, 04 Dec 2009 06:00:00 +0100 3054835 European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer http://www.medworm.com/index.php?rid=3014308&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-11-20.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the approval of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM), the most aggressive type of primary malignant brain cancer. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=3014308 Fri, 20 Nov 2009 14:15:00 +0100 3014308 ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone http://www.medworm.com/index.php?rid=2902431&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0050813-actemra-rheumatoid-200px.jpg Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=2902431 Sat, 17 Oct 2009 21:00:00 +0100 2902431 Roche reports further accelerated sales growth in third quarter http://www.medworm.com/index.php?rid=2892828&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-10-15.htm Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets ; Genentech integration progressing successfully; New Group leadership appointed (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=2892828 Thu, 15 Oct 2009 05:00:00 +0100 2892828 Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer http://www.medworm.com/index.php?rid=2826778&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-24.htm A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=2826778 Thu, 24 Sep 2009 11:10:00 +0100 2826778 Continuous improvements in animal welfare within Roche Research http://www.medworm.com/index.php?rid=2826779&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-24b.htm Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation. (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=2826779 Thu, 24 Sep 2009 07:00:00 +0100 2826779 From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases http://www.medworm.com/index.php?rid=2822612&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-23b.htm New data from several studies presented at ECCO 15 and ESMO 34 confirm unique benefits of Avastin (bevacizumab) and Xeloda (capecitabine) in treatment of colon cancer: Combination of Avastin with standard chemotherapy resulted in shrinkage or disappearance of liver metastases in 78% of patients with advanced colon cancer. A third of patients (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=2822612 Wed, 23 Sep 2009 12:00:00 +0100 2822612 Roche announces results from two early studies which show promise for patients with malignant melanoma http://www.medworm.com/index.php?rid=2822613&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-23.htm New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor (Source: Roche Media News) Roche Media News news http://www.medworm.com/rss/comments.php?id=2822613 Wed, 23 Sep 2009 09:15:00 +0100 2822613